tiprankstipranks
Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim
The Fly

Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim

Guggenheim analyst Michael Schmidt noted that Roche (RHHBY) announced it is voluntarily withdrawing Tecentriq for the treatment of patients with first-line metastatic bladder cancer who are not eligible for cisplatin with PD-L1 positive tumors, or who are not eligible for any platinum-based chemotherapies regardless of PD-L1 status after Imvigor130 failed to meet the co-primary endpoint of overall survival in the final analysis. Given today’s news, platinum doublets without addition of checkpoint inhibitors remain the standard of care for first-line mBC patients, said Schmidt, who thinks this bodes well for the regulatory review of Seagen’s (SGEN) Cohort K data seeking accelerated FDA-approval in cis-ineligible first-line mBC with an FDA decision anticipated in mid-2023. He keeps a Buy rating on Seagen shares.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SGEN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles